Skip to main content
ANRO logo

ANRO · Alto Neuroscience, Inc.

$27.23 +0.16 (+0.59%) At close · Jul 22
Market Cap
$955.61M
Shares
35.09M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Net Income
-$63.24M -2.9%
FY2025 Net Income FY2023–FY2025
Diluted EPS
-$2.19 +12.4%
FY2025 Diluted EPS FY2023–FY2025
Operating Cash Flow
-$51.77M -9.2%
FY2025 Operating Cash Flow FY2023–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023
$55.94M $45.62M $47M $30.29M
$21.89M $20.75M $21.61M $7.52M
$576K $502K $373K
$77.83M $66.36M $68.61M $37.81M
-$77.83M -$66.36M -$68.61M -$37.81M
$2.42M $2.47M $1.38M $1.37M
$6.34M $6.6M $8.85M $2.35M
$3.52M $3.13M $7.18M $1.5M
$0 $0 $0
-$74.31M -$63.24M -$61.43M -$36.31M
USD/shares -$2.19 -$2.50 -$9.73
USD/shares -$2.19 -$2.50 -$9.73
shares 28.85M 24.6M 3.73M
shares 28.85M 24.6M 3.73M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Biotechnology median 8.58×
EV/EBIT
Biotechnology median 26.67×
P/E (TTM)
Biotechnology median 7.06×
Key facts CIK 1999480 CUSIP 02157Q109 13F (30d) 7 filings 7 filers Visit website Investor relations